Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|October 9, 2020

Making Telemedicine Work

Author(s)Chris Aiken, MD

Dr Aiken gives tips to feel more connected to your patient and become more aware of their lives.

Dr Aiken is Instructor in Clinical Psychiatry at the Wake Forest University School of Medicine and the Director of the Mood Treatment Center in Winston-Salem, NC. He is Editor in Chief of The Carlat Psychiatry Reportand Bipolar Disorder Section Co-Editor for Psychiatric Times.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related to this article

covid

October 19th, 2026

New Phase 2 Data on Bezisterim for the Treatment of Long COVID

Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.

Trending on Psychiatric Times

Assessing Interventions for Insomnia in Peri- and Postmenopausal Women

October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News

Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive

ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study

GLP-1 Receptor Agonists May Reinforce Restriction in Patients With Eating Disorders